Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0745411 (irregular bleeding)
 386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Medroxyprogesterone (Depo-Provera), a progesterone used as an injection for 1) treating cancer of the uterus, and 2) an injectable contraceptive, is approved by 69 countries, manufactured in at least 6 countries, and is distributed to 42 countries by the International Planned Parenthood Federation. However, long-term safety studies revealed by 1970 that it caused benign and malignant mammary tumors in dogs. FDA therefore withdrew oral products containing this drug and required a warning for injection labeling. FDA denied approval to the Upjohn Company in March 1978 to manufacture medroxyprogesterone for contraception for the following reasons: 1) safety questions are unresolved; 2) safer contraceptive alternatives are available; 3) irregular bleeding caused by the drug, then treated by estrogen administration imposes an added risk factor and decreases the benefits of a progesterone-only contraceptive; and 4) possible exposure of the fetus poses a risk of congenital malformations, enhanced by prolonged activity of the drug. However, treatment by the drug for uterine cancer is still available.
 ...
PMID:DES and breast cancer. 63 66